Enlivex Therapeutics (ENLV) Expected to Announce Earnings on Wednesday

Enlivex Therapeutics (NASDAQ:ENLV) is expected to post its results before the market opens on Wednesday, February 25th. Analysts expect Enlivex Therapeutics to post earnings of ($0.0863) per share for the quarter.

Enlivex Therapeutics Trading Up 3.0%

Enlivex Therapeutics stock opened at $1.04 on Tuesday. The firm has a market cap of $246.88 million, a P/E ratio of -1.89 and a beta of 1.62. Enlivex Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.10. The firm has a 50-day moving average of $0.96 and a 200-day moving average of $1.04.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ENLV shares. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. HC Wainwright lifted their price target on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 12th. Wall Street Zen lowered shares of Enlivex Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enlivex Therapeutics presently has an average rating of “Hold” and a consensus price target of $13.00.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds have recently modified their holdings of ENLV. Renaissance Technologies LLC increased its stake in shares of Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after acquiring an additional 156,336 shares in the last quarter. HRT Financial LP grew its holdings in Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the period. Jane Street Group LLC grew its holdings in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. Invesco Ltd. bought a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $43,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the third quarter valued at approximately $57,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.